| Stereochemistry | MIXED |
| Molecular Formula | C18H24I3N3O8 |
| Molecular Weight | 791.1119 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 0 / 2 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
COCC(=O)NC1=C(I)C(C(=O)NCC(O)CO)=C(I)C(C(=O)N(C)CC(O)CO)=C1I
InChI
InChIKey=DGAIEPBNLOQYER-UHFFFAOYSA-N
InChI=1S/C18H24I3N3O8/c1-24(4-9(28)6-26)18(31)12-13(19)11(17(30)22-3-8(27)5-25)14(20)16(15(12)21)23-10(29)7-32-2/h8-9,25-28H,3-7H2,1-2H3,(H,22,30)(H,23,29)
Iopromide is a molecule used as a contrast medium. It is a low osmolar, non-ionic contrast agent for intravascular use. It is commonly used in radiographic studies such as intravenous urograms, brain computer tomography (CT) and CT pulmonary angiograms (CTPAs). It appears to increase the risk of biguanide induced lactic acidosis. Interleukins are associated with an increased prevalence of delayed hypersensitivity reactions after iodinated contrast agent administration. Most common adverse reactions (>1%) are headache, nausea, injection site and infusion site reactions, vasodilatation, vomiting, back pain, urinary urgency, chest pain, pain, dysgeusia, and abnormal vision.
CNS Activity
Originator
Approval Year
Doses
Overview
| CYP3A4 | CYP2C9 | CYP2D6 | hERG |
|---|---|---|---|
OverviewOther
| Other Inhibitor | Other Substrate | Other Inducer |
|---|---|---|
Drug as victim
Sourcing
PubMed
Patents
Sample Use Guides
Intra-Arterial: Maximum Total Dose of Ultravist (iopromide) 300 mgI/mL for Cerebral Arteriography is 150 mL, for Peripheral Arteriography is 250 mL. Maximum Total Dose of Ultravist 370 mgI/mL for Coronary Arteriography and Left Ventriculography is 225 mL.
Intravenous: Maximum Total Dose of Ultravist 300 mgI/mL for Excretory Urography is 100 mL. Maximum Total Dose of Ultravist 300 mgI/mL for Contrast Computed Tomography is 200 mL
Route of Administration:
Other
ACTIVE MOIETY
